Skip to content
2000
Volume 6, Issue 1
  • ISSN: 1574-8898
  • E-ISSN: 2212-3954

Abstract

Erection is a neurovascular event characterized by the tumescence of the cavernous bodies that relies upon integration of neural and humoral mechanisms requiring the participation of autonomic and somatic nerves and the integration of numerous spinal and supraspinal sites. Erectile dysfunction (ED) is a highly prevalent problem increasing with age, as well as the major men's sexual concern. Significant advances in the pharmacological treatment of ED have occurred in recent years, most notably after the introduction of sildenafil, the first oral selective phosphodiesterase type 5 inhibitor. Nevertheless, many other oral, local and surgical treatments are available and their efficacy and safety depend on the specific cases. This review provides a comprehensive description of both currently available neurogenic ED treatments and most promising future therapies, including assigned patents.

Loading

Article metrics loading...

/content/journals/prn/10.2174/157488911794079082
2011-01-01
2025-10-30
Loading full text...

Full text loading...

/content/journals/prn/10.2174/157488911794079082
Loading

  • Article Type:
    Research Article
Keyword(s): absorption; anticoagulation therapy; antidepressive drug; anxious; Apomorphine; bioavailability; blood flow; bulbocavernosus reflex; cardiovascular diseases; cavernous nerve; climax; co-dergocrine; corpus cavernosum; cyclic guanosine; demyelinating; depression; diabetes mellitus; dizziness; dopamine agonist; Dopaminergic agonists; dorsomedial; dose; DYSFUNCTION; dyslipidemia; efficacy; Endothelin-1; endothelium; Endothelium-dependent; engorgement; epidemiological evidence; Erectile dysfunction (ED); erections, ejaculation; erythromycin; fibrosis; first-pass metabolism; guanylate-cyclase activators; guanylyl cyclase; headache; hepatic cytochrome; hypercholesterolemia; hypersexuality; hypertension; hypogonadotropic hypogonadism; inflammatory disorder; intracorporeal fibrosis; intraurethral pharmaceutical agents; ischemic optic neuropathy; ketoconazole; levodopa; libido; Lodenafil carbonate; medullary raphe; melanocortins; micropenis; minoxidil, aminophylline; monophosphate; multifactorial; Multiple sclerosis (MS); naltrexone; nasal congestion; neurogenic; neurogenic erectile dysfunction; neurological disorders; Neurophysiology; neurotransmitter; noradranaline; obesity; opium alkaloid; oral dosing; orgasmic; orthostatic hypotension; oxygen; patents; pathology; PDEi; pelvic nerve; pelvic plexus; penile rehabilitation; penis; Peripherally Acting Compounds; pharmacokinetic; phosphodiesterase; phosphodiesterase 5; Phosphodiesterase 5 Inhibitors; placebo; potassium channel inhibitors; potency; prostaglandin; psychogenic; reflexogenic erections; respiratory distress syndrome; rhinitis; sacral spinal cord; serum; Sildenafil citrate; smoking; somatic (pudendal) nerves; Sympathetic preganglionic; symptomatic hypotension; tachycardia; thoracic; thoracolumbar sympathetic; tolerability; trabecular smooth muscle; Trazodone; urogenital symptoms; vascular disease; vasoconstrictor; Yohimbine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test